Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2011-12-27
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S143000
Reexamination Certificate
active
08084478
ABSTRACT:
Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided,wherein R1, R2and R3are each independently selected from hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy and difluoromethoxy; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.
REFERENCES:
patent: 4983731 (1991-01-01), Wagner et al.
patent: 5491172 (1996-02-01), Lee et al.
patent: 6608185 (2003-08-01), Omura et al.
patent: 6624185 (2003-09-01), Glombik et al.
patent: 7138414 (2006-11-01), Schoenafinger et al.
patent: 7453010 (2008-11-01), Bovy et al.
patent: 7749997 (2010-07-01), Birch et al.
patent: 2002/0183384 (2002-12-01), Cornicelli et al.
patent: 2003/0072757 (2003-04-01), Farese et al.
patent: 2004/0102432 (2004-05-01), Sanganee et al.
patent: 2005/0070545 (2005-03-01), Fox et al.
patent: 2007/0123504 (2007-05-01), Bolin et al.
patent: 2007/0155832 (2007-07-01), Haeberlein et al.
patent: 2007/0249620 (2007-10-01), Kurata et al.
patent: 2008/0090876 (2008-04-01), Cheng et al.
patent: 2008/0096874 (2008-04-01), Birch et al.
patent: 2008/0306059 (2008-12-01), Birch et al.
patent: 2009/0048258 (2009-02-01), Ogino et al.
patent: 2009/0093497 (2009-04-01), Bolin et al.
patent: 2009/0197926 (2009-08-01), Birch et al.
patent: 2009/0209602 (2009-08-01), Butlin et al.
patent: 2009/0215779 (2009-08-01), Butlin et al.
patent: 2009/0298853 (2009-12-01), Bauer et al.
patent: 2010/0029727 (2010-02-01), Johnstone et al.
patent: 2010/0160397 (2010-06-01), Birch et al.
patent: 2010/0173958 (2010-07-01), Bennett et al.
patent: 2010/0184813 (2010-07-01), Birch et al.
patent: 10223273 (2003-12-01), None
patent: 1236468 (2002-09-01), None
patent: 2004/067635 (2004-03-01), None
patent: 2005/206492 (2005-08-01), None
patent: 2007/131584 (2007-05-01), None
patent: 2007/191471 (2007-08-01), None
patent: WO 94/26702 (1994-11-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 02/20484 (2002-03-01), None
patent: WO 03/099772 (2003-12-01), None
patent: WO 2004/007455 (2004-01-01), None
patent: WO 2004/047755 (2004-06-01), None
patent: WO 2004/100881 (2004-11-01), None
patent: WO 2005/013907 (2005-02-01), None
patent: WO 2005/044250 (2005-05-01), None
patent: WO 2005/046670 (2005-05-01), None
patent: WO 2005/072740 (2005-08-01), None
patent: WO 2006/004200 (2006-01-01), None
patent: WO 2006/019020 (2006-02-01), None
patent: WO 2006/044775 (2006-04-01), None
patent: WO 2006/064189 (2006-06-01), None
patent: WO 2006/082010 (2006-08-01), None
patent: WO 2006/082952 (2006-08-01), None
patent: WO 2006/113919 (2006-10-01), None
patent: WO 2006/120125 (2006-11-01), None
patent: WO 2006/134317 (2006-12-01), None
patent: WO 2007/016538 (2007-02-01), None
patent: WO 2007/060140 (2007-05-01), None
patent: WO 2007/071966 (2007-06-01), None
patent: WO 2007/126957 (2007-11-01), None
patent: WO 2007/137103 (2007-11-01), None
patent: WO 2007/137107 (2007-11-01), None
patent: WO 2007/138304 (2007-12-01), None
patent: WO 2007/141502 (2007-12-01), None
patent: WO 2007/141517 (2007-12-01), None
patent: WO 2007/141538 (2007-12-01), None
patent: WO 2007/141545 (2007-12-01), None
patent: WO 2007/144571 (2007-12-01), None
patent: WO 2008/011130 (2008-01-01), None
patent: WO 2008/011131 (2008-01-01), None
patent: WO 2008/039007 (2008-04-01), None
patent: WO 2008/039008 (2008-04-01), None
patent: WO 2008/040651 (2008-04-01), None
patent: WO 2008/048991 (2008-04-01), None
patent: WO 2008/067257 (2008-06-01), None
patent: WO 2008/099221 (2008-08-01), None
patent: WO 2008/129319 (2008-10-01), None
patent: WO 2008/134690 (2008-11-01), None
patent: WO 2008/134693 (2008-11-01), None
patent: WO 2008/141976 (2008-11-01), None
patent: WO 2008/148840 (2008-12-01), None
patent: WO 2008/148849 (2008-12-01), None
patent: WO 2008/148851 (2008-12-01), None
patent: WO 2008/148868 (2008-12-01), None
patent: WO 2009/011285 (2009-01-01), None
patent: WO 2009/016462 (2009-02-01), None
patent: WO 2009/024821 (2009-02-01), None
patent: WO 2009/037222 (2009-03-01), None
patent: WO 2009/040410 (2009-04-01), None
patent: WO 2009/071483 (2009-06-01), None
patent: WO 2009/081195 (2009-07-01), None
patent: WO 2009/112445 (2009-09-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design.” Chem Rev. 1996, 96, 3147-3176.
Adcock et al., “Electronic effect of the tricyanomethyl group by carbon-13 and fluorine-19 NMR: nature of aryl fluorine-19 NMR polar field effects in the benzene and naphthalene ring systems” Journal of Organic Chemistry 44 (17): 3004-3017 (1979).
Anderson et al. “Identification of a Form of Acyl-CoA:Cholesterol Acyltransferase Specific to Liver and Intestine in Nonhuman Primates” J Biol Chem 273(41):26747-26754 (1998).
Birch et al. “Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor” J. Med. Chem. 52(6):1558-1568 (2009).
Brown and Goldstein “Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis” Annu Rev Biochem. 52:223-261 (1983).
Burnett and Huff “Avasimibe Pfizer” Curr Opin Investig Drugs 3(9):1328-1333 (2002).
CAPLUS RN 404032-15-1, retrieved from CAPLUS on Jul. 17, 2009.
Cases et al. “ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase” J Biol Chem 273(41):26755-26764 (1998).
Cases et al. “Cloning of DGAT2, a Second Mammalian Diacylglycerol Acyltransferase, and Related Family Members” J. Biol. Chem. 276(42):38870-38876 (2001).
Cases et al. “Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis” Proc Natl Acad Sci U S A. 95(22):13018-13023 (1998).
Chang et al. “Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells” J. Biol. Chem. 268(28):20747-20755 (1993).
Chen et al. “Increased Insulin and Leptin Sensitivity in Mice Lacking ACYL COA: Diacylglycerol Acyltransferase 1” Journal of Clinical Investigation 109(8):1049-1055 (2002).
Chen et al. “Inhibition of Triglyceride Synthesis as a Treatment Strategy for Obesity: Lessons From DGAT1-Deficient Mice” Arteriosclerosis, Thrombosis, and Vascular Biology 25(3): 482-486 (2005).
Chen et al. “Obesity resistance and enhanced glucose metabolismin mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1” J. Clin. Invest. 111(11):1715-1722 (2003).
Coleman “Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine” Methods in Enzymology 209:98-104 (1992).
Field and Salome “Effect of dietary fat saturation, cholesterol and cholestyramine on acyl-CoA: cholesterol acyltransferase activity in rabbit intestinal microsomes” Biochimica et Biophysica Acta 712(3):557-570 (1982).
Hoffman et al. “Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogs” Journal of Medicinal Chemistry 36(8):953-966 (1993).
Hubbard et al. “Antisense and small-molecule modulation of diacylglycerol acyltransferase” Expert Opinion on Therapeutic Patents 17(11): 1331-1339 (2007).
Insull Jr. et al. “Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia” Atherosclerosis 157(1):137-144 (2001).
Lehner and Kuksis “Biosynthesis of triacylglycerols” Prog Lipid Res. 35(2):169-201 (1996).
Oelkers et al. “Characterization of Two Human Genes Encoding Acyl Coenzyme A:Cholesterol Acyltransferase-related Enzymes” J Biol Chem 273(41):26765-26771 (1998).
Robertson et al. “Preclinical Safety Evaluation of Avasimibe i
Butlin Roger John
Plowright Alleyn Thomas
Anderson Rebecca
AsstraZeneca AB
Morgan & Lewis & Bockius, LLP
Otton Alicia L
LandOfFree
Substituted 5- phenylamino- 1, 3,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 5- phenylamino- 1, 3,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 5- phenylamino- 1, 3,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255170